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direct and indirect healthcare costs of type 2 diabetes in Austria. Methods: A 
burden of disease study, which evaluates all kinds of disease burden, like costs, 
quality adjusted life years (QALYs) and disability adjusted life years (DALYs) lost, 
was conducted. This study uses a prevalence-based bottom-up approach and pro-
jects costs over the time horizon of one year. Data were collected via literature 
review, published list prices and hospital records. Costs from published sources 
were used from the societal perspective. The direct costs include hospital, treat-
ment and physician consultation costs. Indirect costs cover patient care giver costs 
as well as work absenteeism. Results: The average costs per year of a Diabetes 
Type 2 are 3,242.91 EUR. Inpatient care is a major contributor to costs, accounting 
for 81% of total costs while drug costs account for an average of 14%. The estimated 
total direct annual cost for all patients diagnosed with type 2 diabetes is 1.2 billion 
EUR. This represents a share of 3.3% of the country´s total healthcare expendi-
tures. The average annual indirect costs for patients with diabetes mellitus type 
2 amounts to 781 million EUR. Compared to the healthy population, the diabetes 
mellitus type 2 population have utility decrements of 251,974 QALYs. Moreover 
type 2 diabetes patients will lose 19,853 DALYs within one year. ConClusions: 
Type 2 diabetes mellitus is a common disease and the prevalence is expected to 
increase considerably in the future. The findings of this study demonstrate the 
high economic import of the disease.
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objeCtives: Although type 2 diabetes (T2DM) has been globally recognised as a 
major public health issue with substantial economic implications, its quantita-
tive impact in some geographical regions is not well documented. This study 
aimed to describe the health care resource utilisation (HCRU) associated with 
T2DM in Africa, Middle East, South Asia, Eurasia and Turkey. Methods: Cross-
sectional data from 8,156 patients recruited across four geographical regions 
(18 countries) was collected as part of the 5th wave of the IDMPS (2011–2012). 
Mean (SD) annual levels of different types of HCRU were estimated and negative 
binomial regression was undertaken to identify drivers of HCRU by region and 
country. Results: Estimated HCRU showed that patients in South Asia (n= 1,195), 
Eurasia (n= 1,843), Africa (n= 2,220) Middle East (n= 2,065) and Turkey (n= 842) expe-
rienced a mean (SD) of 0.4 (1.5), 1.7 (4.1), 0.6 (1.9), 0.3 (1.2) and 1.3 (2.7) hospitalisa-
tions annually. The mean (SD) annual number of diabetes-related inpatient days 
was 1.5 (6.8), 16.0 (30.0), 4.7 (22.7), 1.1 (6.1) and 10.8 (34.3) respectively. The mean 
(SD) annual number of sick days due to diabetes for the same regions were 4.6 
(19.7), 17.5 (35.4), 11.6 (44.4), 1.4 (6.8) and 8.0 (34.4). Presence of macrovascular 
complications was a key driver of incidence of hospitalisations [Incidence Rate 
Ratio - IRR (CI 95%)] in South Asia [3.4 (1.4–8.5)], Eurasia [1.4 (1.1–1.8)], Africa [3.9 
(2.1–7.3)], Middle East [8.9 (4.6–15.7)] and Turkey [2.9 (1.8–4.6)]. Microvascular com-
plications were associated with increased risk of hospitalisations in all regions 
with IRRs (CI 95%) of 3.5 (1.8 – 7.0), 3.4 (2.2 – 5.1), 3.7 (2.2 – 5.1), 1.7 (1.0 – 2.9) 
and 3.4 (2.2 – 5.1) respectively. ConClusions: Results of this study demon-
strate that in South Asia, Eurasia, Africa, Middle East and Turkey, development 
of micro and macrovascular complications are key drivers for economic burden 
of T2DM.
PDB126
healthcare use anD exPenDIture for DIaBetes In BanglaDesh: a 
MatcheD-case-control stuDy
Shariful Islam SM
Ludwig-Maximilians-Universität (LMU), Munich, Germany, Munich, Germany
objeCtives: Diabetes imposes huge social and economic impact on nations. 
However, information on the costs of treating and managing diabetes in develop-
ing countries is limited. The aim of this study was to estimate healthcare use and 
expenditure for diabetes in Bangladesh. Methods: We conducted a matched 
case-control study between January and July 2014 among 591 adults with diag-
nosed diabetes mellitus (DMs) and 591 age, sex, and residence matched persons 
without diabetes mellitus (non-DMs). We recruited DMs from consecutive patients 
and non-DMs from accompanying persons in BIHS hospital in Dhaka, Bangladesh. 
We estimated the impact of diabetes on healthcare use and expenditure by calcu-
lating ratios and differences between DMs and non-DMs and tested for statistical 
difference using t-tests. Results: DMs had two times more days of inpatient 
treatment, 1.3 times more outpatient visits, and 9.7 times more medications 
than non-DMs (all p< 0.005). The total annual per capita expenditure on medical 
care was 6.12 times higher for DMs than non-DMs (USD 635 vs. 104, respectively). 
Among DMs, 9.8% reported not taking any antidiabetic medications, 46.4% took 
metformin, 38.7% sulphonylurea, 40.8% insulin, 38.7% any antihypertensive medi-
cation, and 14.2% took anti-lipids over the preceding 3 months. ConClusions: 
Diabetes significantly increases healthcare use and expenditure and is likely to 
impose a huge economic burden on the healthcare systems in Bangladesh. The 
study highlights the importance of prevention and optimum management of dia-
betes in Bangladesh, and other developing countries, to gain a strong economic 
incentive through implementing multi-sectoral approach and cost-effective pre-
vention strategies.
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literature, there is little if any attempt to quantify it. We aim to quantify the dif-
ference between the efficacy and effectiveness of Metformin in terms of reduc-
ing HbA1c in patients with type-2-diabetes. Methods: First, a systematic review 
was carried out to identify relevant randomized controlled trials (RCTs) and non-
interventional studies (NIS). CENTRAL, MEDLINE (via PubMed) and clinicaltrials.
gov were searched for relevant articles published within the last 20 years. RCTs 
and NIS which evaluated the treatment effects of Metformin in adult patients with 
type-2-diabetes and analyzed glycaemic control by means of change in HbA1c value 
were included. Studies in which Metformin was used as a concomitant antidia-
betic, studies with a study period of less than three months and studies analyzing 
subpopulations were excluded from further research. Only German and English 
papers were eligible. Second, mean values of HbA1c reduction were aggregated in 
a meta-analysis using a random-effects model. Study heterogeneity was assessed 
by the I2-parameter. To test for publication bias we used funnel plots. Results: In 
total 1151 articles were identified. 21 RCTS and 6 NIS were included in the quantita-
tive analysis. Overall HbA1c was reduced by 1.012% (95%-CI: -1.186%; -0.839%). I2 
was 99.911% (RCTs: 99.932; NIS: 97.769) indicating high heterogeneity. The compari-
son of the two settings resulted in a small difference of 0.130% in HbA1c decrease 
between RCTs (-0.953%; 95%CI: -1.188%, -0.717%) and NIS (-1.083%; 95% CI: -1.34%, 
-0.826%). ConClusions: The results of our analysis indicate that the often-men-
tioned gap between clinical studies and real-world application does not exist in the 
treatment of type-2-diabetes with Metformin.
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objeCtives: According to the National Unified Clinical Protocol of Primary and 
Secondary (Specialized) Medical Care, for type 2 diabetes mellitus preparations of 
alpha-lipoic acid (ALA) at high doses are recommended as a pathogenetic therapy 
of painful diabetic neuropathy. The pharmaceutical market of Ukraine proposes 
2 oral formulations of ALA preparations: standard and HRF (High Release form). 
Pharmacokinetic studies [MMW Spezial, Münch. med. Wschr. 1999, 141: page 2] 
showed that comparing with the standard formulation HRF of ALA reduces the 
inter-individual variability in absorption by 58% thus ensuring optimal absorption 
in most patients. The objective of the study was to assess the consumption of oral 
formulations of ALA preparations in the pharmaceutical market of Ukraine and to 
conduct pharmacoeconomic evaluation. Methods: The consumption of 2 oral for-
mulations of ALA preparations was assessed in indicator DDDs/1000 inhabitants/day 
(DIDs). To conduct the pharmacoeconomic evaluation, results of pharmacokinetic 
studies were used [MMW Spezial, Münch. med. Wschr. 1999, 141: page 2]. Results: 
In 2013, the amount of consumption of ALA preparations in the pharmaceutical 
market of Ukraine was 1.79 DIDs. The portion of HR formulation accounts for 5.35% 
of the total amount of consumption and the consumption of the standard oral 
formulation of ALA preparations accounts for 94.65%, respectively. According to 
authors of the study, the indicator of the inter-individual variability in absorption 
was 22% for HRF and 59% – for standard ALA formulation. Thus NNT indicator is 
1/0.37 = 2.7. Calculating the cost of achieving a therapeutically effective plasma 
level in 1 patient on the NNT indicates that the achievement of a therapeutic level 
in the blood plasma needs 2.7 times more costs when administering the standard 
ALA formulation compared to HRF. ConClusions: HR formulation of ALA has a 
higher cost effectiveness compared to the standard oral formulation, which makes 
it more efficient to use.
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objeCtives: To assess medical technologies in order to increase efficiency and 
reduce the cost of thyroid disease treatment. Methods: We made the retrospective 
analysis of 81 patients’s medical records with hypothyroidism that were hospital-
ized to the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). 
The cost of replacement therapy with levothyroxine drugs, which were preferred 
in practice, was analyzed. We also checked the appropriateness of diagnostics and 
specialist consultations according to the Protocol of medical care for patients with 
endocrine system disorders. Results: The result of retrospective analysis of 81 
patients’s medical records with hypothyroidism showed that all patients received 
replacement therapy by levothyroxine. Among them 74 patients were treated with 
drugs of Ukrainian production while 7 patients were taking medicine of foreign 
manufacturer. The cost of pharmacotherapy with foreign medicines was 125% 
more expensive compare to Ukrainian drugs. When comparing diagnostics and 
specialists consultations with a Protocol of medical care for patients with endo-
crine system disorders we have established compliance. However, given the preva-
lence of complications of underlying disease by cardiovascular system disorders 
(in 100% of patients), we consider it necessary to add cardiologist consultation to 
Protocol. ConClusions: It is advisable to use domestic drugs in pharmacotherapy 
of hypothyroidism. Cardiologist consultation should be added to Protocol of medical 
care for patients with hypothyroidism.
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objeCtives: Type 2 diabetes mellitus affects 358,267 individuals in Austria and 
exerts a substantial economic burden on patients, healthcare systems and society. 
The main objective of this study is to analyse the burden of disease as well as the 
